SWHR Urges FDA OWH to Prioritize Inclusion of Pregnant Women in Clinical Trials

SWHR signed on to a comment letter from the Coalition to Advance Maternal Therapeutics (CAMT) regarding the inclusion of pregnant women and lactating women in clinical trials. The letter was sent in response to the US Food and Drug Administration (FDA) Office of Women’s Health (OWH) request for feedback on OWH strategic priorities.

SWHR also send their own comments in response to the OWH request for feedback. SWHR’s comment letter on OWH strategic priorities can be found here.

Read the letter 

SWHR signed on to a comment letter from the Coalition to Advance Maternal Therapeutics (CAMT) regarding the inclusion of pregnant women and lactating women in clinical trials. The letter was sent in response to the US Food and Drug Administration (FDA) Office of Women’s Health (OWH) request for feedback on OWH strategic priorities.

SWHR also send their own comments in response to the OWH request for feedback. SWHR’s comment letter on OWH strategic priorities can be found here.

Read the letter